ANDA Sponsors Should Ask DMF Holders About 'Hidden Facilities'
Generics Firms Urged To Check For Facilities Not Listed In Applications
FDA says 16% of ANDAs have an issue with "hidden facilities" that are listed in drug master files but not the ANDAs they are linked with; industry official offers some tips to bridge this communications gap with DMF holders.
You may also be interested in...
The US FDA has launched the second phase of an effort to improve its inactive ingredients database by replacing confusing potency amounts with maximum daily exposure limits, a change sought by generic drug and excipient manufactures.
The US FDA will not enforce expiration dating requirements for unit-dose repackaging if repackagers follow an alternative approach outlined in final guidance.
A blockchain application for mobile devices was successfully piloted to conduct real-time tracking of a high-cost drug through the “last mile” of the supply chain to the point of dispensing. Such a tool can be useful for manufacturers in tracing their products through the supply chain and complying with a forthcoming mandate of the US FDA Drug Supply Chain Security Act (DSCSA).